What is BYSI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BYSI?

P/E (TTM) is n/a and 52-week range is $0.57 to $2.44 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BYSI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BYSI?

The company profile lists revenue (TTM) near $1M, net income (TTM) near $-6.15B, EPS (TTM) near $-0.16 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Beyondspring Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Florham Park, New Jersey, US, 41.1M shares outstanding, ISIN KYG108301006 when available from company profile and filing metadata.

Beyondspring Inc

$BYSI

Health Care · Biotechnology

IR Run Scenarios

$0.61

-0.56%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 44 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.

Employees

Website

www.beyondspringpharma.com/en/

IPO

2017-03-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)